Jianwei Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianwei Wu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Zian Lu
Department of Orthopaedics, Huashan Hospital Fudan University, No.12 Middle Urumqi Road, Shanghai 200040, China
2 shared publications- Feng Zeng
Artemisinin Research Center, Institute of Science and Technology, The First Affiliated Hospital, The First Clinical Medical School, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication Han Huang
Department of Orthopedics, Huashan Hospital, Fudan University, Shanghai 200000, China
1 shared publication- Han Huang
Department of Orthopaedics, Huashan Hospital Fudan University, No.12 Middle Urumqi Road, Shanghai 200040, China
1 shared publication Haocheng Xu
Department of Orthopedics, Huashan Hospital, Fudan University, Shanghai 200000, China
1 shared publication- Haocheng Xu
Department of Orthopaedics, Huashan Hospital, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- 15 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (1) , 275-289
Proton-Activated Chloride Channel Modulates Motor Function after Acute Spinal Cord Injury
Spinal cord injury (SCI) disrupts motor, sensory, and autonomic functions, profoundly impairing quality of life. Here, we investigate the role of the proton-activated chloride (PAC) channel, encoded by Pacc1, in motor function recovery following SCI. We found that PAC is expressed in the spinal cord, predominantly in microglia, and its expression markedly increases after injury. In Pacc1 knockout mice, motor recovery was significantly improved, accompanied by reduced microgliosis. Moreover, microglia-specific deletion of Pacc1 decreased lesion volume and further enhanced motor recovery, as demonstrated by behavioral assessments. Mechanistically, loss of Pacc1 in microglia suppressed excessive microglial activation and the release of pro-inflammatory cytokines after injury. Together, these findings identify the PAC channel as an injury-induced regulator that aggravates inflammation and impairs motor recovery. Targeting PAC may thus represent a promising therapeutic strategy to mitigate inflammation and promote spinal cord repair after SCI.
- 15 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (1) , 275-289
Proton-Activated Chloride Channel Modulates Motor Function after Acute Spinal Cord Injury
Spinal cord injury (SCI) disrupts motor, sensory, and autonomic functions, profoundly impairing quality of life. Here, we investigate the role of the proton-activated chloride (PAC) channel, encoded by Pacc1, in motor function recovery following SCI. We found that PAC is expressed in the spinal cord, predominantly in microglia, and its expression markedly increases after injury. In Pacc1 knockout mice, motor recovery was significantly improved, accompanied by reduced microgliosis. Moreover, microglia-specific deletion of Pacc1 decreased lesion volume and further enhanced motor recovery, as demonstrated by behavioral assessments. Mechanistically, loss of Pacc1 in microglia suppressed excessive microglial activation and the release of pro-inflammatory cytokines after injury. Together, these findings identify the PAC channel as an injury-induced regulator that aggravates inflammation and impairs motor recovery. Targeting PAC may thus represent a promising therapeutic strategy to mitigate inflammation and promote spinal cord repair after SCI.
- Open Access
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0118
Custom-Made Ce–Mn Bimetallic Nanozyme for the Treatment of Intervertebral Disc Degeneration by Inhibiting Oxidative Stress and Modulating Macrophage M1/M2 Polarization
Intervertebral disc degeneration (IDD)-induced lower back pain (LBP) brings heavy burden worldwide. In the degenerated intervertebral disc, there is an increase in the accumulation of reactive oxygen species (ROS) and the infiltration of M1 macrophages, which leads to abnormal local inflammatory microenvironment and exacerbates IDD. In this study, we developed a novel injectable polyethylene glycol (PEG)-capped cerium ion–manganese ion (Ce–Mn) bimetallic nanozyme (CeMn-PEG) with strong ROS scavenging and M2-type macrophage polarizing abilities to efficiently alleviate IDD. In vitro experiments demonstrated that CeMn-PEG effectively scavenged excess ROS in both nucleus pulposus (NP) and RAW264.7 cells. In addition, we found that CeMn-PEG markedly protected NP cells from H 2 O 2 -induced overproduction of inflammatory cytokines, excessive cell apoptosis and autophagy, and imbalance between extracellular matrix (ECM) degradation. Moreover, CeMn-PEG induced macrophages to transition from the M1 phenotype to the M2 phenotype and the increased M2-type macrophages could alleviate H 2 O 2 -induced ECM degradation and cell apoptosis in NP cells. In a puncture-induced mouse IDD model, CeMn-PEG treatment could effectively ameliorate the progression of disc degeneration and mitigate puncture-induced mechanical hyperalgesia. Thus, our study demonstrated the effectiveness of CeMn-PEG as a novel treatment strategy for the treatment of IDD and a range of other inflammatory diseases.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 28, 0118
Open AccessCustom-Made Ce–Mn Bimetallic Nanozyme for the Treatment of Intervertebral Disc Degeneration by Inhibiting Oxidative Stress and Modulating Macrophage M1/M2 Polarization
Intervertebral disc degeneration (IDD)-induced lower back pain (LBP) brings heavy burden worldwide. In the degenerated intervertebral disc, there is an increase in the accumulation of reactive oxygen species (ROS) and the infiltration of M1 macrophages, which leads to abnormal local inflammatory microenvironment and exacerbates IDD. In this study, we developed a novel injectable polyethylene glycol (PEG)-capped cerium ion–manganese ion (Ce–Mn) bimetallic nanozyme (CeMn-PEG) with strong ROS scavenging and M2-type macrophage polarizing abilities to efficiently alleviate IDD. In vitro experiments demonstrated that CeMn-PEG effectively scavenged excess ROS in both nucleus pulposus (NP) and RAW264.7 cells. In addition, we found that CeMn-PEG markedly protected NP cells from H 2 O 2 -induced overproduction of inflammatory cytokines, excessive cell apoptosis and autophagy, and imbalance between extracellular matrix (ECM) degradation. Moreover, CeMn-PEG induced macrophages to transition from the M1 phenotype to the M2 phenotype and the increased M2-type macrophages could alleviate H 2 O 2 -induced ECM degradation and cell apoptosis in NP cells. In a puncture-induced mouse IDD model, CeMn-PEG treatment could effectively ameliorate the progression of disc degeneration and mitigate puncture-induced mechanical hyperalgesia. Thus, our study demonstrated the effectiveness of CeMn-PEG as a novel treatment strategy for the treatment of IDD and a range of other inflammatory diseases.